Eli Lilly and Alchemab Therapeutics Collaborate on Novel ALS Therapies

Collaboration Agreement:
Eli Lilly and Alchemab Therapeutics have entered into a collaboration to discover, develop, and commercialize up to five novel therapeutic antibodies for amyotrophic lateral sclerosis (ALS)145.

Technology Platform:
Alchemab's technology platform uses patient samples from individuals with slow rates of disease progression to identify antibodies associated with resilience. This approach aims to uncover protective immune mechanisms that can be replicated in therapeutic candidates145.

Financial Terms:
Alchemab will receive an undisclosed upfront payment from Lilly and is eligible for milestone payments and royalties based on the success of the project125.

Unmet Needs:
ALS is a rare and fatal neurodegenerative disease with no cure. The average life expectancy from onset to death is two to four years, highlighting the urgent need for effective therapeutics145.

Alchemab’s Pipeline:
Alchemab's pipeline includes neurodegeneration and oncology programs targeting ALS, Alzheimer's, Huntington's, and solid tumors, leveraging their novel antibody discovery platform4.

Lilly’s ALS Efforts:
This collaboration is part of Lilly’s broader efforts in ALS drug development, following a $45 million deal with QurAlis in late 2024 to develop preclinical candidates for ALS and dementia4.

Sources:

1. https://manufacturingchemist.com/eli-lilly-alchemab-therapeutics-collaboration-als-antibody-discovery-development

2. https://news.futunn.com/en/post/52027258/on-thursday-alchemab-therapeutics-entered-a-collaboration-with-eli-lilly

4. https://www.biopharmatrend.com/post/1102-eli-lilly-partners-with-uks-alchemab-to-develop-new-als-antibodies/

5. https://www.prnewswire.com/news-releases/alchemab-therapeutics-enters-into-collaboration-with-lilly-to-discover-research-and-develop-novel-therapies-for-als-302346205.html